Renal risk scores: Progress and prospects

Slides:

Advertisements

Similar presentations

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

Advertisements

Reduced renal function in patients with simple renal cysts

Volume 70, Issue 10, Pages (November 2006)

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Propofol-related green urine

Viper venom for diabetic nephropathy

Anemia management in chronic kidney disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

Volume 83, Issue 3, Pages (March 2013)

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Stem cells for kidney repair: useful tool for acute renal failure?

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients Demetrios J. Kutsogiannis, R.T.Noel.

Volume 79, Issue 12, Pages (June 2011)

Viper venom for diabetic nephropathy

Volume 61, Issue 2, Pages (February 2002)

Gudrun Hatlen, Solfrid Romundstad, Stein I. Hallan

Volume 80, Issue 10, Pages (November 2011)

Volume 57, Issue 5, Pages (May 2000)

Peter Rossing, Philip Hougaard, Hans-Henrik Parving

Volume 77, Issue 1, Pages 6-8 (January 2010)

Volume 63, Issue 4, Pages (April 2003)

Volume 66, Issue 3, Pages (September 2004)

Volume 68, Issue 5, Pages (November 2005)

C.Y. Hsu, J.D. Ordoñez, G.M. Chertow, D. Fan, C.E. McCulloch, A.S. Go

Volume 84, Issue 5, Pages (November 2013)

Anemia as a risk factor for chronic kidney disease

Comorbidity and confounding in end-stage renal disease

Volume 70, Issue 11, Pages (December 2006)

Volume 61, Issue 6, Pages (June 2002)

Volume 77, Issue 2, Pages (January 2010)

Volume 87, Issue 2, Pages (February 2015)

Volume 74, Issue 8, Pages (October 2008)

Volume 70, Issue 12, Pages (December 2006)

Volume 67, Pages S48-S51 (January 2005)

Volume 65, Issue 6, Pages (June 2004)

Volume 69, Issue 9, Pages (May 2006)

Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation? Pantelis A. Sarafidis, Luis.

Volume 73, Issue 12, Pages (June 2008)

Should kidney donors be genotyped for APOL1 risk alleles?

Volume 69, Issue 12, Pages (June 2006)

Proteinuria and hypertensive nephrosclerosis in African Americans

Elevated risk of stroke among patients with end-stage renal disease

Alternate-day dialysis may be needed for hemodialysis patients

Nephrology Crossword: Peritoneal Dialysis

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Volume 76, Issue 8, Pages (October 2009)

Volume 67, Issue 4, Pages (April 2005)

Reduced renal function in patients with simple renal cysts

Volume 78, Issue 5, Pages (September 2010)

Nephrology Crossword: Glomerulonephritis

V.R. Sørensen, P.M. Hansen, J. Heaf, B. Feldt-Rasmussen

Volume 74, Issue 5, Pages (September 2008)

Volume 85, Issue 5, Pages (May 2014)

Volume 71, Issue 12, Pages (June 2007)

Volume 73, Issue 9, Pages (May 2008)

Volume 77, Issue 12, Pages (June 2010)

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Volume 80, Issue 10, Pages (November 2011)

Michael R. Lattanzio, Matthew R. Weir Kidney International

Volume 64, Issue 4, Pages (October 2003)

Volume 75, Issue 7, Pages (April 2009)

Changes to the End-Stage Renal Disease Quality Incentive Program

Volume 64, Issue 4, Pages (October 2003)

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes Steven M. Brunelli, Ravi Thadhani,

Dana V. Rizk, David G. Warnock Kidney International

Volume 80, Issue 9, Pages (November 2011)

Friends, social networks, and progressive chronic kidney disease

Volume 57, Pages S44-S48 (April 2000)

Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.

Stephen Pastan, J. Michael Soucie, William M. McClellan

Presentation transcript:

Renal risk scores: Progress and prospects M.W. Taal, B.M. Brenner Kidney International Volume 73, Issue 11, Pages 1216-1219 (June 2008) DOI: 10.1038/ki.2008.36 Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 1 Kaplan Meier curve showing the incidence of ESRD among patients with type 2 diabetes and diabetic nephropathy included in the Reduction of Endpoints in NIDDM with Angiotensin II Antagonist Losartan (RENAAL) Study, stratified into quartiles of a risk score derived from baseline serum creatinine, urine albumin/creatinine ratio, serum albumin, and hemoglobin. Kidney International 2008 73, 1216-1219DOI: (10.1038/ki.2008.36) Copyright © 2008 International Society of Nephrology Terms and Conditions